semaglutide mash approval targets molecular pathways beyond weight loss https://open.spotify.com/episode/5BQT8WX94k4NAJ5OlIuNBy... For Audience who prefer

[7] Starting mid-2026, Medicare beneficiaries with obesity + heart disease risk may pay ~$50/month copays

Lifestyle Foundations Were Not Built During the Medication Phase GLP-1 medications make it easier to eat less, but they do not automatically preserve muscle, improve metabolic flexibility, or rebuild movement habits

Our patches come with clear backing for a clear reason: it works

Practical timeline expectations For researchers who decide to proceed with a combined protocol despite the unknown risks, realistic timeline expectations help set appropriate milestones for evaluation

M., Qu Y., Lenox S., Lewis M

Key takeaways: Semaglutide 25 mg produced greater average weight loss compared with orforglipron 36 mg